A novel method for evaluating the antimicrobial activity of tuberculosis treatment regimens

International Journal of Tuberculosis and Lung Disease

Volumn 7, Issue 7, 2003, Pages 684-689

  Gillespie, Stephen H ^a   Charalambous, B M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Clinical trials; Drug effects; Mathematical model

Indexed keywords

CIPROFLOXACIN; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ANALYTIC METHOD; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; CELL VIABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EARLY DIAGNOSIS; EVALUATION; HUMAN; IMMUNE RESPONSE; INTERMETHOD COMPARISON; MATHEMATICAL MODEL; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPUTUM EXAMINATION; TIME SERIES ANALYSIS; TREATMENT FAILURE; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; CELL SURVIVAL; CIPROFLOXACIN; DRUG ADMINISTRATION SCHEDULE; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MODELS, STATISTICAL; RIFAMPIN; SPUTUM; TUBERCULOSIS, PULMONARY;

EID: 0038789097     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Pablos-Mendez A. Working alliance for TB drug development, Cape Town, South Africa, February 8th, 2000. Int J Tuberc Lung Dis 2000; 4: 489-490.
2. Kennedy N, Berger L, Curram J, et al. Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Clin Infect Dis 1996; 22: 827-833.
3. East African/British Medical Research Councils. Controlled trial of five short course regimens of chemotherapy regimens for pulmonary tuberculosis. Am Rev Resp Dis 1981; 123: 165-170.
4. Fox W, Ellard G A, Mitchison D A. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3 (Suppl 2): S231-S279.
5. Aber V R, Nunn A J. Short term chemotherapy of tuberculosis. Factors affecting relapse following short term chemotherapy. Bull Int Union Tuberc 1978; 53: 276-280.
6. Mitchison D A. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis 1993; 147: 1062-1063.
7. Wayne L G. Dormancy of Mycobacterium tuberculosis and latency of disease. Eur J Clin Microbiol Infect Dis 1994; 13: 908-914.
8. Mitchison D A. The action of anti-tuberculosis drugs in shortcourse chemotherapy. Tubercle 1985; 66: 219-225.
9. Lipsitch M, Levin B R. Population dynamics of tuberculosis treatment: mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance. Int J Tuberc Lung Dis 1998; 2: 187-199.
10. Fox W. The current status of short course chemotherapy. Bull Int Union Tuberc 1978; 53: 268-280.
11. Gillespie S H, Gosling R D, Charalambous B M. A re-iterative method for calculating the early bactericidal activity of anti-tuberculosis drugs. Am J Respir Crit Care Med 2002; 166: 31-35.
12. Kennedy N, Fox R, Kisyombe G M, et al. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. Am Rev Respir Dis 1993; 148: 1547-1551.
13. Mitchison D A. Treatment of tuberculosis. The Mitchell lecture 1979. J R Coll Physicians Lond 1980; 14: 91-99.
14. Combs D L, O'Brien R J, Geiter L J. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med 1990; 112: 397-406.
15. Kennedy N, Whitelaw F M, Gutmann J, et al. Clinical features and serum beta 2-microglobulin levels in HIV-1 positive and negative Tanzanian patients with tuberculosis. Int J STD AIDS 1995; 6: 278-283.
16. Hellyer T J, Desjardin L E, Teixeira L, et al. Detection of viable Mycobacterium tuberculosis by reverse transcriptase - strand displacement amplification of MRNA. J Clin Microbiol 1999; 37: 518-523.
17. Desjardin L E, Perkins M D, Wolski K, et al. Measurement of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapy. Am J Respir Crit Care Med 1999; 160: 203-210.
18. Cangelosi G A, Brabant W H. Depletion of pre-16S rRNA in starved Escherichia coli cells. J Bacteriol 1997; 179: 4457-4463.
19. Wallis R S, Perkins M, Phillips M, et al. Induction of the antigen 85 complex of Mycobacterium tuberculosis in sputum: a determinant of outcome in pulmonary tuberculosis treatment. J Infect Dis 1998; 178: 1115-1121.